top of page
EXE-LOGO-MEDIXAL-BLANC.png

QUALITY / REACTIVITY / ADAPTABILITY / SIMPLICITY

MEDIXAL specializes in tailored solutions for pharmaceutical companies,

marketing authorization holder, ensuring seamless compliance

with strict French and European regulations.

As a licensed pharmaceutical operator (status of Etablissement pharmaceutique exploitant), we offer expertise in all fields to pharmaceutical companies looking for a partner to distribute their drugs on the French market.

We are the Coordinator of the entire post-clinical activities in France:

Market access, Exploitant, Compliance, Distribution, Warehousing & Logistic, Promotional

and non promotionnals activities with sales reps.

We are accountable for the responsibilities related to the distribution of pharmaceutical products in France.

MEDIXAL is committed to quality, innocuity and safety.

We simplify complexity, enabling you to focus on your business growth.

shutterstock_479711074.png

Why MEDIXAL

Unique official point of contact acting as local representative.

MEDIXAL staff has decades of experience with French regulations
in big pharma.

Unlike a large company, MEDIXAL is a company in its own right:

  - Agile

  - Reactive

MEDIXAL is a privileged partner of the Pharmafield group.

MEDIXAL adapts to the client in order to provide a tailor-made service in a very heavy regulatory context.

Choosing MEDIXAL is to offer simplicity in a complicated regulatory context enabling you to focus on your business growth.

CONTACT

US

Address

23 Boulevard Vital Bouhot

92200 NEUILLY SUR SEINE FRANCE

Email

Phone

+33 7 88 37 60 32

If you wish to report a product quality complaint, an adverse effect, or a medical information request related to a product distributed by Medixal, please send your request to:

Contact FRANCE

By submitting this form, I agree that the information entered will be used to contact me as part of the commercial relationship that may result from this request.

Thanks for submitting!

Site mis à jour en avril 2026

Référence : MED-COM-2025-007-v3

bottom of page